

UC San Diego

UC San Diego Previously Published Works

Title

Cholestenic acid, an endogenous cholesterol metabolite, is a potent γ -secretase modulator.

Permalink

<https://escholarship.org/uc/item/71t2x8wr>

Journal

Molecular neurodegeneration, 10(1)

ISSN

1750-1326

Authors

Jung, Joo In
Price, Ashleigh R
Ladd, Thomas B
et al.

Publication Date

2015-07-01

DOI

10.1186/s13024-015-0021-z

Peer reviewed

RESEARCH ARTICLE

Open Access



Cholestenic acid, an endogenous cholesterol metabolite, is a potent γ -secretase modulator

Joo In Jung^{1,2,3}, Ashleigh R. Price^{1,2,3}, Thomas B. Ladd^{1,2,3}, Yong Ran^{1,2,3}, Hyo-Jin Park^{1,2,3}, Carolina Ceballos-Diaz^{1,2,3}, Lisa A. Smithson^{1,2,3}, Günther Hochhaus⁴, Yufei Tang⁴, Rajender Akula⁵, Saritha Ba⁵, Edward H. Koo^{6,8}, Gideon Shapiro^{7*}, Kevin M. Felsenstein^{1,2,3*} and Todd E. Golde^{1,2,3*}

Abstract

Background: Amyloid- β (A β) 42 has been implicated as the initiating molecule in the pathogenesis of Alzheimer's disease (AD); thus, therapeutic strategies that target A β 42 are of great interest. γ -Secretase modulators (GSMs) are small molecules that selectively decrease A β 42. We have previously reported that many acidic steroids are GSMs with potencies ranging in the low to mid micromolar concentration with 5 β -cholanic acid being the most potent steroid identified GSM with half maximal effective concentration (EC₅₀) of 5.7 μ M.

Results: We find that the endogenous cholesterol metabolite, 3 β -hydroxy-5-cholestenic acid (CA), is a steroid GSM with enhanced potency (EC₅₀ of 250 nM) relative to 5 β -cholanic acid. CA i) is found in human plasma at ~100-300 nM concentrations ii) has the typical acidic GSM signature of decreasing A β 42 and increasing A β 38 levels iii) is active in *in vitro* γ -secretase assay iv) is made in the brain. To test if CA acts as an endogenous GSM, we used Cyp27a1 knockout (Cyp27a1^{-/-}) and Cyp7b1 knockout (Cyp7b1^{-/-}) mice to investigate if manipulation of cholesterol metabolism pathways relevant to CA formation would affect brain A β 42 levels. Our data show that Cyp27a1^{-/-} had increased brain A β 42, whereas Cyp7b1^{-/-} mice had decreased brain A β 42 levels; however, peripheral dosing of up to 100 mg/kg CA did not affect brain A β levels. Structure-activity relationship (SAR) studies with multiple known and novel CA analogs studies failed to reveal CA analogs with increased potency.

Conclusion: These data suggest that CA may act as an endogenous GSM within the brain. Although it is conceptually attractive to try and increase the levels of CA in the brain for prevention of AD, our data suggest that this will not be easily accomplished.

Keywords: Cholestenic acid, γ -secretase modulator (GSM), Amyloid, Alzheimer disease, Cholesterol, Steroid, Bile acid, Cytochrome P450

Background

Accumulation of aggregated amyloid β peptides (A β) in the brain is proposed to be a key trigger in a complex neuropathological cascade that leads to Alzheimer's disease (AD). A β is produced from the amyloid precursor protein (APP) through sequential proteolytic cleavages [1]. APP is first cleaved by β -secretase to produce a

soluble APP β and a membrane anchored APP carboxyl terminal fragment (CTF β). The CTF β is then cleaved by γ -secretase to produce extracellular A β peptides and APP-intracellular domain (AICD) fragments. Notably, a number of A β peptides are normally produced, with A β 40 being the most abundant species with minor species including, but not limited to, A β 37, 38, 39 and 42 routinely observed in most studies. These various species are not produced by simple classic endoproteolysis at multiple sites, but appear to arise from both variation in the initial substrate cleavage site which produces longer A β s (i.e., A β 48, A β 49, and A β 51) and the cognate

* Correspondence: gideon.shapiro@gmail.com; kfelsenstein@ufl.edu; tgolde@ufl.edu

⁷Pharmore, Inc., Gainesville, FL 32653, USA

¹Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA

Full list of author information is available at the end of the article

AICD, which is then followed by multiple cycles of step-wise, carboxyl-peptidase like cleavages, all of which are mediated by γ -secretase. Although all A β peptides normally produced appear to accumulate in the human AD brain, the minor A β 42 species is typically the most prevalent form that accumulates in the brain parenchyma [2, 3]. Additional lines of evidence further support the concept A β 42 is the most pathogenic isoform [4], whereas A β 40 may, under some circumstances, be a protective isoform [5, 6]. Many early onset familial AD (FAD) mutations linked with APP and Presenilin (PSEN, the catalytic subunit of γ -secretase) increase the relative levels of A β 42 [7–10]. *In vitro* studies show that A β 1–42 has a much stronger tendency to aggregate than A β 1–40 [11]. In AD mouse model, A β 42 plays a role as a seeding molecule for amyloid deposition but A β 40 [6] does not. In fact, A β 40 appears to prevent mice from amyloid deposition [5, 12]. Moreover, A β x–42 is the earliest detectable A β isoform in the brain parenchyma [13–16]. The role of other shorter carboxyl-terminal truncated species is at this point unclear, though it is hypothesized that they may behave like A β 40 [5, 17]. Altogether, there is ample rationale that decreasing the levels of A β 42 could be a prophylactic approach to prevent accumulation of A β and, thereby, delay or prevent the development of AD.

There have been studies demonstrating that production and processing of A β can be influenced by membrane lipid composition [18–21]. In particular, membrane cholesterol appears to play an important role [18]. APP-CTF β and γ -secretase are found in lipid rafts, composed primarily of cholesterol [18]. Further, it has been shown that cholesterol directly binds to the APP-CTF β substrate [22, 23]. The interdependent interactions among the three components (APP-CTF β , γ -secretase, and cholesterol) are postulated to create the optimal microenvironment for A β production. Indeed, it has been reported that γ -secretase activity is largely dependent on the amount of cholesterol, which affects A β production as a result [18, 24] though others have not reproduced this finding [25]. These observations suggest the potential for modulating γ -secretase activity and thus altering the overall A β levels or the ratios of A β isoforms produced by steroid derivatives as cholesterol surrogates.

Previously, we have reported steroid carboxylic acid γ -secretase modulators (GSMs) [26]. Numerous acidic steroids decrease A β 42 levels and increase A β 38 levels without changing total A β or A β 40 levels [26]. Acidic steroid GSMs have gross structural similarity to the established-NSAID based GSMs in that a carboxylic acid group, that is key for GSM activity, is attached by a carbon tether chain to a highly lipophilic core structure [26, 27]. 5 β -Cholanic acid (ursocholic acid) was the most potent steroid GSM identified in our previous study with


an EC₅₀ of 5.7 μ M, but the endogenous bile acids, lithocholic acid and ursocholic acid, were also found to be GSMs [26]. Mechanistically, GSMs decrease production of A β 42 selectively by promoting step-wise γ -secretase cleavage and, thus, inherently increase shorter A β peptides [28, 29]. Because γ -secretase cleavage activity participates in a broad spectrum of cellular signaling mechanisms (i.e., Notch-1) [30], indiscriminate inhibition of γ -secretase activity has been essentially abandoned as a therapeutic approach for AD due to debilitating side effects associated with target-based toxicity. In contrast, GSMs do not alter overall γ -secretase activity, appear to be relatively selective for APP, and are, therefore, thought to be an intrinsically safe mechanistic approach to AD therapy; however, it has been challenging to identify GSMs that are potent, have sufficient brain penetrance, and lack off-target toxicity.

Considering that GSMs derived from synthetic compounds have toxicity issues that are not associated with target-based toxicity, we have explored whether other naturally occurring acidic steroids might have sufficient potency to be therapeutically useful. An extended screening identified 3 β -hydroxy-5-cholestenoic acid (CA) as a highly potent GSM with an EC₅₀ for A β 42 lowering of 250 nM. As CA is produced endogenously during the course of cholesterol elimination in many extrahepatic organs including the brain [31, 32] and is present in human plasma at concentrations near its EC₅₀ for GSM activity, we explored whether CA might function endogenously as a GSM. Our results showed that Cyp27a1–/– [33, 34] and Cyp7b1–/– [35] mice that reduce or increase brain CA, respectively, resulted in the predicted brain A β 42 changes consistent with the hypothesis that CA is an endogenous GSM. Peripheral dosing of CA in wild type mice dramatically increased plasma CA levels, but not brain A β levels, suggesting limited brain exposure of peripheral CA. Structure-activity relationship (SAR) with multiple known and novel CA analogs studies failed to reveal CA analogs with increased potency. These studies show that though CA is a potent GSM that may act within the brain to regulate A β 42 levels, exogenous administration of CA is not likely to be therapeutically useful for lowering A β 42.

Results

CA is a potent GSM

Based on previous studies that showed a number of acidic steroids are GSMs [26], we continued to test other additional acidic steroids for GSM activity. These studies revealed that the endogenous cholesterol metabolite CA (Fig. 1a) had potent GSM activity. In cell-based assays, the EC₅₀ value for decreasing A β 42 levels was 250 nM and, consistent with other acidic steroid GSMs, A β 38 increased without alterations in total A β



(Fig. 1b). CA's GSM activity was further confirmed by IP/MS analysis using the conditioned media produced from CHO2B7 cells, which revealed selective lowering of A β 42 and increased A β 38 (Fig. 1c). To assess whether CA has a direct effect on γ -secretase, we performed *in vitro* γ -secretase cleavage assays (Fig. 1d-f). In these assays CA treatment decreased A β 42 production by 51 % without any significant changes in total A β levels when the A β levels were compared to DMSO control (Fig. 1d).

Compound E (Cmpd E), a non-selective γ -secretase inhibitor, decreased both A β 42 (91 %) and total A β (77 %) production significantly (Fig. 1d). These A β levels demonstrate the initial A β levels in the assays. IP/MS A β and AICD profiles from the *in vitro* assay are illustrated in Fig. 1e and f, respectively. Again CA decreased A β 42 and increased A β 38 (Fig. 1e) and, as noted with previous studies of GSMs, did not affect ϵ -site utilizations (AICD49-99 and AICD50-99) (Fig. 1f). Next, we utilized primary

mouse postnatal day 0 (P0) neuron-glia cultures of wild-type mice to determine the effect of CA on endogenous mouse A β (mA β) levels (Fig. 1g-j). CA decreased mA β 42 production by ~60 % at 3 μ M and by ~75 % at 10 μ M (Fig. 1g) and increased A β 38 production at 10 μ M (Fig. 1h) resulting in a significant decrease in the A β 42:A β 38 ratio at both concentrations (Fig. 1i). Thus, confirming that CA acts as GSM on primary brain cells.

Loss of Cyp27a1 and Cyp7b1 alters mouse brain A β 42

To determine whether CA levels could affect A β 42 production *in vivo*, we assessed A β levels in both Cyp27a1^{+/+}, Cyp27a1^{+/-} and Cyp27a1^{-/-} mice brains and Cyp7b1^{+/+}, Cyp7b1^{+/-} and Cyp7b1^{-/-} mice brains. In the brain, Cyp27a1 catalyzes the synthesis of CA from 27-OHC and Cyp7b1 catabolizes CA (Fig. 2a). From the previous literature, loss of Cyp27a1 has been shown to eliminate the levels of 27-OHC production in the mouse brain, suggesting decreased CA levels, whereas loss of Cyp7b1 increases mouse brain CA levels from ~30 nM to ~300 nM [36]. In humans with loss of function

mutations in *CYP27A1* and *CYP7B1*, there is reduced and elevated CSF or plasma CA, respectively [36]. For our studies, mouse brains were harvested at 3 months and endogenous mouse A β levels measured by ELISA. Fig. 2b shows mA β 42/mA β 40 ratio measured from the Cyp27a1 mouse brains. There was a significant 23 % increase in the mA β 42/mA β 40 ratio in Cyp27a1^{-/-} mice compared to Cyp27a1^{+/+} (Fig. 2b). Because Cyp27a1 mice were poor breeders, we did not obtain enough animals for an accurate measurement of brain A β 38 levels. Conversely, Cyp7b1^{-/-} mice showed a significant 21 % decrease in mA β 42/mA β 40 ratio (Fig. 2c) and a significant 25 % increase in mA β 38/mA β 40 ratio (Fig. 2d) compared to control Cyp7b1^{+/+} mice. In all cases, the ratios of mA β 40/mA β 42 and mA β 38/mA β 40 in heterozygous Cyp27a1 or Cyp7b1 mice (Cyp27a1^{+/-} or Cyp7b1^{+/-}) were intermediate between wild type and null animals, although the differences were not statistically significant. We attempted to observe amyloid plaque pathology in the context of Cyp7b1 or Cyp27a1 deficiency. Extensive efforts were made to breed APP_(KM670/671NL+V717F) CRND8




Fig. 2 The effects of Cyp27a1 and Cyp7b1 genetic reductions on brain mA β levels. **a** CA is found in the acidic cholesterol elimination pathway. Cholesterol is hydrolyzed by Cyp27a1 to produce 27-hydroxycholesterol (27-OHC) and CA sequentially. CA is further metabolized by Cyp7b1 generating CA derivatives, 7 α -hydroxy-cholestenic acid (7 α -OH-CA) and 7 α -hydroxy-4-oxo-cholestenic acid (7 α -OH-4-CA). Genetic deletion of Cyp27a1 is predicted to decrease endogenous CA levels, whereas the deletion of Cyp7b1 is predicted to accumulate CA. **b** Cyp27a1 (-/-) increased brain mA β 42/A β 40 ratio compared to Cyp27a1 (+/+) by ~20 %. **c-d** Cyp7b1 (-/-) decreased the ratio between mA β 42 to mA β 40 by ~20 % compared to Cyp7b1 (+/+), whereas increased the ratio of mA β 38/A β 40 by ~30 %. 6–8 mice were tested in the group. The results were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons. **p* < 0.05

transgenic mice onto or *Cyp7b1*^{-/-} genotype, but these efforts were unsuccessful. Though a few APP^{+/+} on the *Cyp7b1*^{-/-} backgrounds were generated, none of these survived past 3 months of age. Thus, we were unable to evaluate the effects of loss of *Cyp7b1* on amyloid deposition.

Intraperitoneal injections of CA did not alter mouse brain A β levels

To test the acute effect of CA *in vivo*, CA (30 mg/kg) or GSM-1 (30 mg/kg), a potent GSM compound (Fig. 3), was given to wild type mice, and the brains were harvested after 30 min, 1, 2, and 3 h. While the positive control GSM-1 showed the expected A β modulation in mouse brains after three hours post intraperitoneal (IP) injection [37], there were no changes in A β levels after CA administration (Fig. 3a-c). It should be noted in these studies that the half-life ($T_{1/2}$) for CA in humans

is reported to be 90 min [38]. Next, a dose-response study was performed with CA given to wild type mice at 30, 60, 75, and 100 mg/kg doses with brains harvested 3 h after dosing. CA was well tolerated in mice up to the highest concentration (100 mg/kg). The Fig. 3d demonstrates CA plasma concentrations after injections of various doses in C57BL/6 mice. The standard curve for CA measurement showed a linear response with the limit of quantification of 100 ng/mL (~250 nM), which is close to physiological plasma CA concentration (100–300 nM) [39, 36, 40]. When different doses (30, 60, 75, 100 mg/kg) of CA were injected, plasma CA concentrations increased in dose dependent manner from 200 ng/mL (~500 nM) at 30 mg/kg dose to 4000 ng/mL (~10 μ M) at 100 mg/kg dose (Fig. 3d). This might indicate some non-linearity in pharmacokinetics of CA. No significant effects of CA on mA β 42, mA β 38, and total mA β compared to the vehicle-injected control were




Fig. 3 mAb levels in the brains are measured after intraperitoneal (IP) injections of racemic mixture of CA in C57BL/6 and CF-1 mice (wild-type mice). At varying doses and time-points, CA did not show acute effects on brain mAb₄₂, mAb₃₈, and total mAb levels. CA was administered at 30 mg/kg, 60 mg/kg, 75 mg/kg and 100 mg/kg and the brains were harvest 30 min after the injections in C57BL/6 or CF-1 mice. In addition, this was performed in time-course manner at 30 mg/kg. The brains were harvested at different time points (30 min, 1 h, 2 h and 3 h). The representative results of IP injections of GSM-1 and CA at 30 mg/kg at 1-h time point for mAb₄₂ (a), mAb₃₈ (b), and total A β (c) are demonstrated by mouse A β ELISAs. Solutol-based vehicle is utilized as a control and 6 mice were tested per group. (d) CA levels in the plasma in the wild type mice ($n = 3-6$) after IP injections at multiple doses are demonstrated. With the gradual increase in dosage (30 mg/kg, 60 mg/kg, 75 mg/kg, and 100 mg/kg), the plasma CA levels have increased. The results were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons. (*** $p < 0.001$, ** $p < 0.01$)

observed up to the highest 100 mg/kg dose (data not shown).

GSM activity of CA analogs

We had previously screened 170 commercially available steroids and identified 5 β -cholanic acid as the most potent steroid GSM within that set of compounds [26]. 5 β -Cholanic acid **1** (Fig. 4) decreased A β 42 with an EC₅₀ of 5.7 μ M [26]. In this report, we have identified CA **2a** as a potent GSM with an EC₅₀ of 250 nM for decreasing A β 42. As such, **2a** was comparable in potency to an optimized GSM clinical candidate phenylacetic acid EVP-0962 **3** and to preclinical tool compound GSM-1 **4**, as representative reference compounds from the carboxylic acid chemotype (Fig. 4).

A striking structural feature of CA relative to previous potent GSMs is the extended C5 alkylene tether linking the carboxylate group to the lipophilic core steroid nucleus. To date, potent GSMs such as **3** and **4** have been acetic acids in which the carboxylate group is linked to a core lipophilic moiety by a single carbon atom. To evaluate the effects of the alkylene tether, the structural-activity relationship (SAR) for CA analogs varying the tether from 3 methylenes to 7 methylenes (C3-C7) was examined (Table 1). The synthetic chemistry processes for both 25-(R) and 25-(S) pure diastereomers of CA, as well as the other CA analogs in Table 1, are

illustrated and detailed in Additional file 1. Shorter tether analogs **5** (C3 tether analog) and **6** (C4 tether analog) displayed an order of magnitude lowering of potency with EC₅₀ values of ~2.0 μ M. The extended C6 and C7 tether analogs **10** and **11** exhibited a slight decline in potency (EC₅₀ = 391 nM and 513 nM respectively) relative to the baseline C5 analog **7**.

The SAR around the optimal C5 tether structure was elucidated with the analogs **2a**, **2b**, **7**, **8** and **9**. The 25-(S)-CA, the methyl group diastereomer **2b**, was about 2-fold less potent than the 25-(R)-CA **2a**. The simple unsubstituted C5 methylene tether analog **7** displaying an EC₅₀ of ~110 nM was more potent than **2a**. The corresponding α,β -unsaturated analog **8** was virtually equipotent to **7**. This steroid SAR at the α -carbon to the carboxylic acid group differs markedly from the SAR of PAA GSMs such as compound **3** (Fig. 4) where methyl substitution increases potency. Difluoro analog **9** prepared to favor the putative active ionized carboxylate, in fact, exhibited an order of magnitude loss in potency relative to the other C5 analogs.

We further explored the SAR of endogenous CA catabolites found in the acidic pathway (Fig. 5a). 27-OHC, the precursor of CA, is inactive as a GSM since it is missing the critical carboxylate group. CA is then converted to 7 α -OH-CA and then to 7 α -OH-3-CA, therefore we tested them for GSM activity in dose dependent




Fig. 4 Chemical structures of acidic steroid type- and phenylacetic acid (PAA) type-GSMs with their EC₅₀ for decreasing A β 42. 5 β -Cholanic acid (**1**) has a four-ring structure with a 4-carbon side chain on carbon 17 and its EC₅₀ for decreasing A β 42 is ~5.7 μ M. 25(R)-cholestenoic acid (**2a**) has the same four-ring structure with an additional hydroxyl group on carbon 3 and a 6-carbon side chain on carbon 17. For this molecule, the EC₅₀ is at ~250 nM. EVP-0015962 (**3**), (R)-2-(5-chloro-6-(2,2,2-trifluoroethoxy)-4'-(trifluoromethyl)biphenyl-3-yl)-3-cyclobutylpropanoic acid, shows GSM activity at EC₅₀ of 67 nM from the previous literature. GSM-1 (**4**) has the two phenyl rings with the carboxylic acid functional group. The EC₅₀ for GSM-1 is at 92 nM

Table 1 CA analogs EC₅₀ for lowering Aβ₄₂










R ₁	Cmpd#	Aβ ₄₂ EC ₅₀ (nM)
	5	1780
	6	1960
	7	110
	8	148
	2a	250
	2b	501
	9	2193
	10	391

Table 1 CA analogs EC₅₀ for lowering Aβ₄₂ (Continued)

	11	513
--	----	-----

EC₅₀=half maximal effective concentration

studies (Fig. 5a). Both 7α-OH-CA and 7α-OH-3-CA demonstrated GSM activity but were not as potent as CA (Fig. 5a and b). Additionally, we aimed to substitute fluorine (F) at the carbon 3 and 7 positions of the CA catabolites as such fluorine substitutions can block metabolism (**12–13** in Table 2). Replacement of a 3-OH group of CA with a 3β-F group could be readily achieved to give **12** using standard methods. Somewhat surprisingly this modification in **12** resulted in great reduction in GSM potency. Attempts to synthesize the 7-F analog of CA were unsuccessful by routes based on standard diethylaminosulfur trifluoride (DAST) reaction of a corresponding 7-OH intermediate. 7-F delta-5-ene allyl fluoride steroid compounds could be isolated by DAST reaction, however these compounds demonstrated instability in our and previous studies [41, 42]. We also synthesized 3-deoxy-CA **13** based on our previous GSM SAR findings with cholenic acid analogs [26] and this demonstrated an EC₅₀ of 670nM, approximately 3-fold less potent than CA. Collectively, these data demonstrate that endogenous **2b** CA is a relatively optimized steroid-GSM.

Carboxylic acid tether combined to PAA chemotypes did not show GSM activities

As phenyl acetic acid (PAA) chemotype GSMs have low nanomolar potencies for decreasing Aβ₄₂ (Fig. 4, compound **3**), we examined whether increasing the length of the carboxylate tether to the PAA moiety could provide a path to further potency increases. The structures of the compounds synthesized are illustrated in Fig. 6a (the synthesis schemes are provided in Additional file 1). Bi-phenyl moieties (Fig. 6) were selected because they showed optimized drug potencies for GSM effects in previous studies [37, 43, 44]; however, no studies have been investigated regarding the PAA chemotype GSMs combined with the extended alkylene tether. Therefore, we decided to examine whether or not this feature can enhance potencies. We tested for potential GSM activity of these compounds by measuring Aβ₄₂ levels at 300nM and 3 μM (Fig. 6b-c); however, these analogs did not demonstrate GSM activities at either concentration. Altogether, these data indicate that the increased potency observed with the C5 carboxylate tether appears to be specific to the steroid based GSMs and does not extend to other acid GSM chemotypes.





Table 2 Fluorine and deoxy CA analogs EC₅₀ for lowering Aβ42


			
R ₁	R ₂	Cmpd #	Aβ42 EC ₅₀ (nM)
β-F	α-H	12	8906
β-H	β-H	13	671

EC₅₀=half maximal effective concentration

Discussion

In this study, we identified CA as a potent acidic GSM with an EC₅₀ for lowering Aβ42 of ~250 nM, a concentration well within the normal range of CA levels in human plasma (~100-300 nM). This data raised the possibility that CA was an endogenous GSM and that increasing brain CA levels might be a safe approach to lower brain Aβ42 levels. Peripheral dosing of CA, however, did not lower brain Aβ42 despite extremely high CA levels in the plasma (~10 μM), indicating that either CA does appear to readily cross the blood brain barrier or, if it does, is rapidly exported from the brain. Unfortunately, using our methodology, we were not able to accurately measure CA levels with sufficient sensitivity to accurately measure CA levels in the brains of these mice.

Given the potency of CA as a GSM, we explored whether mice with genetic deletions of Cyp27a1 [33, 34] and Cyp7b1 [35], the two enzymes regulating CA levels



in the brain [31], showed alterations in mAβ42 levels. We found that the mAβ42/mAβ40 ratio was increased in the *Cyp27a1*^{-/-} mice and mAβ42/mAβ40 ratio was decreased in *Cyp7b1*^{-/-} mice, where CA levels were shown to decrease or increase CA levels, respectively [36]. Given that these shifts in ratio in these knockout mice are precisely what would be predicted if CA demonstrated GSM activity, we concluded that CA is likely to be a bona fide endogenous GSM synthesized in a cholesterol elimination pathway in brain [31]. Given the challenges of measuring levels of endogenous Aβ outside of the brain in wild type mice, we attempted to generate *Cyp7b1*^{-/-}, APP^{+/-} (CRND8) mice. Despite extensive

efforts, we were unable to generate mice with this genotype that lived past 3 months. We did not attempt to cross the CRND8 mice with *Cyp27a1*^{-/-} mice, because *Cyp27a1*^{-/-} mice were even less fecund than the *Cyp7b1*^{-/-} mice. Future studies in humans with genetic loss of function of *CYP27A1* that causes cerebrotendinous xanthomatosis (CTX) [45, 36] or with genetic loss of function of *CYP7B1* deficiency that causes liver failure in children or spastic paraplegia 5 (SPG5) in adults [46, 39, 36], might help to further establish the likelihood that CA is an endogenous GSM, as these patients show altered CA levels and would be predicted to have altered Aβ42/Aβ40 ratios [39, 36]; however, due to the small

number of patients with these rare disorders, and the severe disease induced by loss of these CYP enzymes, such studies may be challenging to sufficiently power and control.

Building off our previous studies to examine a large number of steroids for GSM and inverse GSM (iGSM) activity [26], we synthesized a number of analogs to see if we can further increase potency. From these studies, we can conclude that CA seems to represent a relatively optimized steroid GSM, especially the C5 alkene tether linking the carboxylate group to the steroid backbone which appears to be optimal in length for maximizing steroid GSM potency. Indeed, there was a significant increase in GSM potency upon increasing the tether length from C3 to C5, but there was only a moderate loss of potency for increased C6 and C7 tether. Based on the observations from extended CA tether analogs, we explored the effects of C5 alkene tether carboxylates on other acidic GSM “scaffolds”. In all cases examined, this “grafting” approach decreased potency, indicating that the position of the carboxylate group for optimal GSM potency is dependent on the overall structure of the molecule. Further modifications along the steroid backbone all decreased GSM activity relative to CA. For example, both endogenous CA metabolites 7 α -OH-CA and 7 α -OH-3-CA maintained GSM activity, but were less potent than CA.

Our findings that CA and other steroids can modify A β production expand the growing number of studies that demonstrate how cholesterol and other steroids can modulate A β profiles [47–54]. Of particular interest are studies showing that cholesterol binds to APP CTF β [22, 23], albeit with low affinity, as this might suggest that CA, a cholesterol metabolite, could also interact with CTF β . Our studies also show that CA behaves much like classic acidic GSMs and like all GSMs, exhibit a fairly flat SAR. Moreover, membrane lipids have been shown to alter the profile of A β produced [55], and therefore it is theoretically possible that CA could alter γ -secretase in a similar manner. However, given the nanomolar potency of CA and the aforementioned flat SAR, we think that this mechanism of action is unlikely. As our data show that it is challenging to generate CA analogs that retain potency, we have not attempted to generate CA analogs that could be used for affinity studies to identify primary binding sites. Given the nanomolar potency of CA, we speculate that it almost certainly interacts with PSEN/ γ -secretase. However, as we have previously hypothesized, we would propose that most GSMs alter γ -secretase through a complex interaction involving both substrate and γ -secretase and possibly even other lipid membrane components [56, 57, 26, 58, 59]. Such a model is consistent with data showing that GSM effects are extremely sensitive to mutations within the substrate

[59, 58, 60] and could explain why different GSM affinity probes have been shown to bind PSEN, PEN2 or C99 [56, 61–63]. It is important to consider that demonstrating binding with such a probe to a certain component does not rule out interaction with the other components, due to limitations where the reactive groups can be placed on the GSM affinity probes and the requirement for photoaffinity probes to have its photoaffinity label be in very close proximity to the bound protein.

In summary, although the endogenous metabolite CA is a potent γ -secretase modulator, i) its lack of ability to lower brain A β 42 following peripheral dosing and ii) the inability to identify additional endogenous CA analogs with increased potency, suggests that pursuing CA or CA analogs for further preclinical development is not likely to be fruitful. Recent data show that CA can be toxic to primary mouse motor neuron in cultures [36] and raises concerns for pursuing CA or CA derivative as possible new small molecule therapeutics for AD. As the immediate precursor of CA, 27-OHC cholesterol, readily crosses the blood brain barrier, a pro-drug approach using a modified 27-OHC might be considered as an alternative strategy; however, emerging data that elevated 27-OHC may be a risk factor for osteoporosis and breast cancer, raises concerns about a 27-OHC cholesterol prodrug strategy to increase CA levels as well [64, 65].

Methods

Cell culture and drug treatment

Chinese hamster ovary (CHO) cells stably overexpressing APP695 (CHO-2B7 cells) [66] were grown in Ham's F-12 medium (Life Technologies) supplemented with 10 % fetal bovine serum and 100 units/ml of penicillin and 100 μ g/ml streptomycin. Cells were grown at 37 °C in a humidified atmosphere containing 5 % CO₂ in tissue culture plates (Costar). The cells were harvested at confluence and then utilized for biochemical analyses. Compounds were dissolved in dimethyl sulfoxide (DMSO) and screened in CHO-2B7 cells. The cells were incubated for 16 h in the presence of the compound diluted into OptiMEM-reduced serum medium (Life Technologies, Carlsbad, CA, USA) containing 1 % fetal bovine serum. Compounds used for our study were either purchased from Avanti Polar Lipids, Inc. or synthesized by SAI Life Sciences Ltd. The synthesis schemes of the newly synthesized compounds are demonstrated in Additional file 1.

In vitro γ -secretase assay

Broken cell assays were performed with slight modifications from the previous studies [67, 18]. The membrane derived from the H4 neuroglioma cells overexpressing APP695wt were prepared by carbonate extraction and incubated at 37 °C for 2 h with CA at various

concentrations. A β levels were quantified by sandwich ELISAs. For A β and AICD spectra, the recombinant C100Flag proteins were overexpressed and purified from *Escherichia coli* BL21 using a HiTrap Q-column (GE Life Science, Little Chalfont, U.K.) [68, 69, 58]. The membrane containing γ -secretase was isolated from the CHO S-1 cell line using sodium carbonate (100 mM, pH 11.0) [70]. For the *in vitro* γ -secretase assay, C100Flag recombinant protein at 25 μ M was incubated with the membrane (100 μ g/mL) in the presence of CA (20 μ M) and DMSO in 150 mM sodium citrate buffer (pH 6.8) containing complete protease inhibitor (Roche, Indianapolis, IN) for 2 h at 37 °C.

Mice

All procedures were performed according to the National Institute of Health Guide for the Care and Use of Experimental Animals and were approved by the University of Florida Institutional Animal Care and Use Committee. The Cyp27a1 $^{-/-}$ (B6.129-Cyp27a1tm1Elt/J) and Cyp7b1 $^{-/-}$ (B6.129S-Cyp7b1tmRus/J) strains were obtained from Jackson Laboratory (Bar Harbor, ME). Cyp27a1 $^{-/-}$ mice were bred with C57BL/6 in order to produce the heterozygous littermates of Cyp27a1, and Cyp7b1 $^{-/-}$ mice were bred with C57BL/6 mice to produce the heterozygous Cyp7b1 littermates. The wild type, heterozygous, and knockout littermates of Cyp27a1 and Cyp7b1 mice were generated from Cyp27a1 $^{+/-}$ X Cyp27a1 $^{+/-}$ and Cyp7b1 $^{+/-}$ X Cyp7b1 $^{+/-}$, respectively.

Primary mixed neuron-glia culture

Primary mixed neuron-glia cultures were prepared from postnatal day 0 (P0) C3HBL/6 mouse brains (Harlan Labs). Cerebral cortices were dissected from P0 mouse brains and were dissociated in 2 mg/ml papain (Worthington) and 50 μ g/mL DNase I (Sigma) at 37 °C for 20 min. They were then washed three times in sterile Hank's balanced salt solution (HBSS) to inactivate the papain and switched to 5 % fetal bovine serum (HyClone) in Neurobasal-A growth media (Gibco), which includes 0.5 mM L-glutamine (Gibco), 0.5 mM GlutaMax (Life Technologies), 0.01 % antibiotic-antimycotic (Gibco), and 0.02 % SM1 supplement (Stemcell). The tissue mixture was then triturated three times using a 5 mL pipette followed by a Pasteur pipette, and strained through a 70 μ m cell strainer. The cell mixture was then centrifuged at 200 \times g for 3 min, and resuspended in fresh Neurobasal-A media. They were then plated onto poly-D-lysine coated 96well plates at 100,000 cells/well. Cells were maintained in the Neurobasal-A growth media mentioned above without fetal bovine serum (FBS) at 37 °C in a humidified 5 % CO₂ chamber.

CA IP injections

25(R)-CA powder was initially dissolved in DMSO (<4.5 % in the final mixture) and then combined with polyethylene glycol (15)-hydroxystearate (Solutol), ethanol, and water at a ratio of (15:10:75). One molar equivalent of sodium hydroxide was added to the mixture [71, 72]. We performed CA intraperitoneal (IP) injections to wild-type mice (C57BL/6 or CF-1). The mice were injected with 25(R)-CA on the right side of the abdomen. The injections have been performed with various time points (30 min, 1 h, 2 h, and 3 h) and with multiple doses (30 mg per kg (mg/kg), 60 mg/kg, 75 mg/kg and 100 mg/kg). The number of each cohort is 6–8. We used 30 mg/kg of CA for the time-course experiments, and for the dose-response experiments the end-point was set at 30 min. The brains and serum are harvested and frozen for brain A β extraction.

Brain A β extraction

The mouse brains were harvested at the age of 3 months. The brains were weighed and recorded. The Diethylamine/Sodium Chloride (DEA/NaCl) extraction buffer (0.4 % DEA) was added to each sample and homogenized using a sonicator. The samples were transferred to a poly-carbonate centrifuge tube and spun down at 50,000 \times g for 30 min at 4 °C. The supernatant was loaded on the vacuum manifold with the appropriate number of HLB Oasis columns. The samples were loaded on the conditioned column, filtered, and eluted using prepared elution buffer (90 % Methanol, 2 % NH₄OH). The eluates are concentrated using the Thermo-Savant SpeedVac concentrator for a minimum of 2 h at 55 °C with radiant heat. The concentrated samples are reconstituted in a blocking buffer (0.67 % Bovine serum albumin (BSA)) at the appropriate volume.

Plasma CA analysis

The plasma samples were extracted using published solid phase extraction method [72] and analyzed by HPLC-MS-MS. Briefly, 0.1 ml mouse plasma samples after adding 20 μ l of D3-CA as internal standard were preconditioned with 1.4 ml of ethanol (99.9 %), and 0.5 ml of water, centrifuged at 4 °C, 4000 rpm for 10 min. This solution was then loaded onto a Sep-Pak tC18 (SPE1) solid phase extraction cartridge which were preconditioned with 70 % ethanol. The sample was washed with one column volume of 70 % ethanol then eluted from the column by 2 + 1 ml of 99.9 % ethanol; it was dried in centrifuge evaporator. The residue was reconstituted in 100 μ l of isopropanol. It was oxidized by adding 1 ml of 50 mM phosphate buffer (pH = 7) containing 3 μ l of cholesterol oxidase and incubated at 37 °C for 1 h, quenched with 1.9 ml of methanol. The mixture was further processed by adding 150 μ l glacial

acetic acid and 1 smidgen (about 80 mg) GP reagent {1-(carboxymethyl) pyridinium chloride hydrazide} and incubated at room temperature overnight in the dark. On the next day, a second solid phase extraction [73] was employed to separate the derivatized CA from the excess derivatization reagent using the following: Sep-pak C18 (SPE 2, different from SPE1) cartridge with 1 column volume of 99.9 % methanol and 1 column volume of 10 % methanol, after application of the sample wash with 10 % methanol, then elute with 2*1 ml of 100 % methanol. Mix 200 µl of the elution solution with 50 µl of water to obtain 250 µl of 80/20 (methanol/water, v/v) samples. 20 µl was injected onto HPLC-MS-MS for analysis.

HPLC-MS-MS conditions: HPLC contains a Perkin Elmer series 200 autosampler and a Perkin Elmer series 200 pump, MS-MS was Waters Quattro LC-Z, ES positive mode, Cone voltage 45 volts, collision energy 30volts, Desolvation temperature 350 °C. Source block temperature 120 °C. MS/MS transitions: CA 549.0/470.0; D3-CA 552.0/473.0. HPLC mobile phase was 80/20 Methanol/water(v/v) containing 0.1 %Formic Acid, HPLC column was ThermoFisher Hypersil Gold, 50*2.1 mm, 1.9 µ, flow rate 0.2 ml/min. Injection volume 20 µl, run time 4 min, CA retention time 1.4 min.

Antibodies and ELISAs

Monoclonal antibodies to Aβ were generated by the Mayo Clinic Immunology Core facilities (Jacksonville, FL, USA). Ab5 recognizes an epitope in the amino terminus of Aβ (Aβ1-16), recognizes both monomeric and aggregated Aβ, and is human specific. Ab13.1.1. was raised against Aβ35-40 and is specific for Aβx-40, and exhibits minimal cross-reactivity with other Aβ peptides. Ab 2.1.3 was raised against Aβ35-42 and is specific for Aβx-42. The Aβ38 antibody (Ab38), supplied by P. Mehta (Institute of Basic Research, Staten Island, NY, USA), specifically recognizes Aβx-38 and shows no cross-reactivity with other Aβ peptides [74]. For cell-based screens, Aβ was captured from conditioned medium with either Ab5, Ab38, Ab13.1.1, or Ab2.1.3 (coated at 10-50 µg/ml in EC buffer: 5 mM NaH₂PO₄-H₂O, 20 mM Na₂HPO₄, 400 mM NaCl, 2.5 mM EDTA-full name, 151.5 µM BSA, 813 µM CHAPS, and 7.7 mM Na₃N) on Immulon 4HBX Flat-Bottom Microfilter 96-well plates (Thermo Scientific, Waltham, MA, USA). Total Aβ level was determined by capture with Ab5 and detected with horseradish peroxidase (HRP)-conjugated 4G8 (a monoclonal antibody against Aβ17-24; Covance, Waltham, MA, USA) with the other Aβ peptides detected with HRP-conjugated Ab5. For the cell-free assay and measuring mouse endogenous Aβ, HRP-conjugated 4G8 was used as the secondary detection antibody. Aβ standards (Bachem, King of Prussia,

PA, USA) were prepared by dissolving in hexafluoroisopropanol (HFIP) at 1 mg/ml with sonication, dried under nitrogen, resuspended at 2 mg/ml HFIP, sonicated again and dried under nitrogen. The resulting Aβ was resuspended in 0.01 % ammonium hydroxide, portioned into aliquots in EC buffer, and frozen at -80 °C. Following these steps, the Aβ is monomeric, as determined by size-exclusion chromatography.

Immunoprecipitation-Mass spectrometry

Conditioned media from the CHO-2B7 cells and the samples prepared from *in vitro* γ-secretase studies were used to analyze Aβ and AICD profiles using matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry analysis. The secreted Aβ peptides were analyzed as previously described with the following modifications [2, 75, 76]. Briefly, the Aβ peptides were immunoprecipitated using Ab5 recognizing the Aβ1-16 epitope [77] and sheep anti-mouse IgG magnetic Dynabeads (Life Technologies, catalog no. 11201D) and the AICD fragments were captured using anti-Flag M2 magnetic beads (Sigma). The samples were washed and eluted with 10 µM solution of 0.1 % trifluoroacetic acid (TFA) in water. Eluted samples were mixed 2:1 with saturated α-cyano-4-hydroxycinnamic acid (CHCA) matrix (Sigma) in acetonitrile: methanol (60:40 %) and loaded onto a CHCA pretreated MSP 96 target plate-polished steel (Bruker, Billerica, MA, USA - Part No.224989). Samples were analyzed using a Bruker Microflex LRF-MALDI-TOF mass spectrometer.

Statistics

In vitro data were expressed and graphed as the mean ± SEM using GraphPad Prism 5 software. Analysis was by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons, and was by two-way analysis of variance (ANOVA) followed by bonferroni post-hoc testing for group differences. The level of significance was set at $p < 0.05$ in all tests.

Additional file

Additional file 1: Schematics of syntheses of (25R)-cholestenoic acid and its analogs.

Abbreviations

Aβ: Amyloid-β; AD: Alzheimer's disease; APP: Amyloid precursor protein; AICD: APP intracellular domain; CTF: APP carboxyl terminal fragment; CA: Cholestenic acid; Cyp: Cytochrome P450; CHO: Chinese hamster ovary; CTX: Cerebrotendinous xanthomatosis; GSM: γ-secretase modulator; NSAID: Non-steroidal anti-inflammatory drug; SPG5: Spastic paraplegia 5; SAR: Structure-activity relationship.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JJ participated in study design, performed in vitro and cell-based immunoassays, analyzed data, and drafted manuscript. APR and LAS participated in animal study design and performed ELISA. TBL and YR performed in vitro and cell-based assays. HJP and CCD performed primary neuronal culture and ELISA. GH and YT participated in pharmacokinetics study and performed LC-MS/MS. RA and SB synthesized CA analogs, which were designed by GS. EHK was involved in experimental interpretation and manuscript editing. GS, KMF, and TEG participated in study design and coordination and in manuscript preparation and editing. All authors read and approved the final manuscript.

Acknowledgements

We thank Patricia Joy for critical reading of this manuscript. This study was funded in NIH NIA P01 AG020206 grant (EHK and TEG).

Author details

¹Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL 32610, USA. ²Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA. ³McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL 32610, USA. ⁴College of Pharmacy, University of Florida, Gainesville, FL 32610, USA. ⁵SAI Life Sciences Ltd., Turkapally AP500078, India. ⁶Department of Neuroscience, University of California, La Jolla, San Diego, CA 92093, USA. ⁷Pharmore, Inc., Gainesville, FL 32653, USA. ⁸Departments of Medicine and Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore.

Received: 6 April 2015 Accepted: 29 May 2015

Published online: 14 July 2015

References

1. Golde TE, Eckman CB, Younkin SG. Biochemical detection of A β isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. *Biochim Biophys Acta*. 2000;1502(1):172–87. doi:10.1016/S0925-4439(00)00043-0.
2. Wang R, Sweeney D, Gandy SE, Sisodia SS. The Profile of Soluble Amyloid β Protein in Cultured Cell Media: detection and quantification of amyloid β protein and variants by immunoprecipitation-mass spectrometry. *J Biol Chem*. 1996;271(50):31894–902.
3. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. *Science* (New York, NY). 1994;264(5163):1336–40.
4. Younkin S. The role of A beta 42 in Alzheimer's disease. *J Physiol Paris*. 1998;92:289–92.
5. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, et al. A β 40 Inhibits Amyloid Deposition In Vivo. *J Neurosci*. 2007;27(3):627–33. doi:10.1523/JNEUROSCI.4849-06.2007.
6. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. *Neuron*. 2005;47:191–9.
7. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer's Disease-Linked Presenilin 1 Variants Elevate A β 1–42/1–40 Ratio In Vitro and In Vivo. *Neuron*. 1996;17(5):1005–13. doi:http://dx.doi.org/10.1016/S0896-6273(00)80230-5.
8. Duff K, Eckman C, Zehr C, Yu X, Prada C-M, Perez-tur J, et al. Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1. *Nature*. 1996;383(6602):710–3.
9. Scheuner D. Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med*. 1996;2:864–70. doi:10.1038/nm0896-864.
10. Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, et al. Enhancement of amyloid β 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. *Neurosci Lett*. 1999;265(1):61–3. doi:http://dx.doi.org/10.1016/S0304-3940(99)00187-1.
11. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the Responsible Protein Aggregates from The Innocent Bystanders*. *Annual Review of Neuroscience*. 2003;26(1):267–98. doi:10.1146/annurev.neuro.26.010302.081142.
12. Wang R, Wang B, He W, Zheng H. Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology. *Journal of Biological Chemistry*. 2006;281(22):15330–6. doi:10.1074/jbc.M512574200.
13. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's b-peptide from biological fluids. *Nature*. 1992;359(6393):325–7.
14. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: Evidence that an initially deposited species is A β 42(43). *Neuron*. 1994;13(1):45–53. doi:10.1016/0896-6273(94)90458-8.
15. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, et al. Amyloid β Protein (A β) in Alzheimer's Disease Brain. *J Biol Chem*. 1995;270(13):7013–6. doi:10.1074/jbc.270.13.7013.
16. Moore B, Chakrabarty P, Levites Y, Kukar T, Baine A-M, Moroni T, et al. Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. *Alzheimer's Research & Therapy*. 2012;4(3):18.
17. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. A β 42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice. *Neuron*. 2005;47(2):191–9. doi:10.1016/j.neuron.2005.06.030.
18. Wahle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, et al. Cholesterol-Dependent γ -Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains. *Neurobiol Dis*. 2002;9(1):11–23. doi:10.1006/nbdi.2001.0470.
19. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer β -amyloid precursor protein depends on lipid rafts. *The Journal of Cell Biology*. 2003;160(1):113–23. doi:10.1083/jcb.200207113.
20. Song C, Liao S. Cholestenoic Acid Is a Naturally Occurring Ligand for Liver X Receptor α . *Endocrinology*. 2000;141(11):4180–4. doi:10.1210/en.141.11.4180.
21. Golde TE, Eckman CB. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. *Drug Discovery Today*. 2001;6(20):1049–55. doi:10.1016/S1359-6446(01)01965-1.
22. Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*. 2010;1801(8):975–82. doi:10.1016/j.bbalip.2010.03.008.
23. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, et al. The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol. *Science*. 2012;336(6085):1168–71. doi:10.1126/science.1219988.
24. Grimm MOW, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C. Independent Inhibition of Alzheimer Disease β - and γ -Secretase Cleavage by Lowered Cholesterol Levels. *Journal of Biological Chemistry*. 2008;283(17):11302–11. doi:10.1074/jbc.M801520200.
25. Levin-Allerhand JA, Lominska CE, Wang J, Smith JD. 17 α -estradiol and 17 β -estradiol treatments are effective in lowering cerebral amyloid- β levels in A β PP5WE transgenic mice. *Journal of Alzheimer's Disease*. 2002;4(6):449–57.
26. Jung JJ, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, et al. Steroids as γ -secretase modulators. *FASEB J*. 2013;27:3775–85. doi:10.1096/fj.12-225649.
27. Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate γ -secretase cleavage. *Curr Top Med Chem*. 2008;8(1):47–53.
28. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity. *Nature*. 2001;414(6860):212–6. http://www.nature.com/nature/journal/v414/n6860/full/414212a.html.
29. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo. *The Journal of Clinical Investigation*. 2003;112(3):440–9. doi:10.1172/JCI18162.
30. Beel AJ, Sanders CR. Substrate specificity of γ -secretase and other intramembrane proteases. *Cell Mol Life Sci*. 2008;65(9):1311–34. doi:10.1007/s00018-008-7462-2.
31. Meaney S, Heverin M, Panzenboeck U, Ekström L, Axelsson M, Andersson U, et al. Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7 α -hydroxy-3-oxo-4-cholestenoic acid. *Journal of Lipid Research*. 2007;48(4):944–51. doi:10.1194/jlr.M600529-JLR200.
32. Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of Disease: inborn errors of bile acid synthesis. *Nat Clin Pract Gastroenterol Hepatol*. 2008;5(8):456–68.
33. Rosen H, Reshef A, Maeda N, Lippoldt A, Shpizen S, Triger L, et al. Markedly Reduced Bile Acid Synthesis but Maintained Levels of Cholesterol and Vitamin

- D Metabolites in Mice with Disrupted Sterol 27-Hydroxylase Gene. *Journal of Biological Chemistry*. 1998;273(24):14805–12. doi:10.1074/jbc.273.24.14805.
34. Honda A, Salen G, Matsuzaki Y, Batta AK, Xu G, Leitersdorf E, et al. Differences in hepatic levels of intermediates in bile acid biosynthesis between Cyp27^{-/-} mice and CTX. *Journal of Lipid Research*. 2001;42(2):291–300.
 35. Li-Hawkins J, Lund EG, Turley SD, Russell DW. Disruption of the Oxysterol 7 α -Hydroxylase Gene in Mice. *Journal of Biological Chemistry*. 2000;275(22):16536–42. doi:10.1074/jbc.M001811200.
 36. Theofilopoulos S, Griffiths WJ, Crick PJ, Yang S, Meljon A, Ogundare M, et al. Cholestenic acids regulate motor neuron survival via liver X receptors. *The Journal of Clinical Investigation*. 2014;124(11):4829–42. doi:10.1172/jci68506.
 37. Page RM, Baumann K, Tomioka M, Pérez-Revuelta BI, Fukumori A, Jacobsen H, et al. Generation of A β 38 and A β 42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and γ -Secretase Modulation. *J Biol Chem*. 2008;283(2):677–83. doi:10.1074/jbc.M708754200.
 38. Babiker A, Andersson O, Lindblom D, van der Linden J, Wiklund B, Lütjohann D, et al. Elimination of cholesterol as cholestenic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. *Journal of Lipid Research*. 1999;40(8):1417–25.
 39. Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7 α -hydroxylase gene causes severe neonatal liver disease. *The Journal of Clinical Investigation*. 1998;102(9):1690–703.
 40. Ogundare M, Theofilopoulos S, Lockhart A, Hall LJ, Arenas E, Sjövall J, et al. Cerebrospinal Fluid Steroidomics: Are Bioactive Bile Acids Present in Brain? *Journal of Biological Chemistry*. 2010;285(7):4666–79. doi:10.1074/jbc.M109.086678.
 41. Khan SN, Kim BJ, Kim H-S. Synthesis and antimicrobial activity of 7-fluoro-3-aminosteroids. *Bioorganic & Medicinal Chemistry Letters*. 2007;17(18):5139–42. doi:http://dx.doi.org/10.1016/j.bmcl.2007.07.001.
 42. Marwah P, Thoden JB, Powell DR, Lardy HA. Steroidal allylic fluorination using diethylaminosulfur trifluoride: A convenient method for the synthesis of 3 β -acetoxo-7 α -and 7 β -fluoroandrost-5-en-17-one. *Steroids*. 1996;61(8):453–60. doi:http://dx.doi.org/10.1016/0039-128X(96)00092-X.
 43. Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, et al. In vitro and in vivo profiling of CHF5022 and CHF5074: Two β -amyloid1–42 lowering agents. *Pharmacological Research*. 2007;55(4):318–28. doi:http://dx.doi.org/10.1016/j.phrs.2006.12.010.
 44. Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, et al. Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β -Amyloid1–42 Secretion. *Journal of Medicinal Chemistry*. 2005;48(18):5705–20. doi:10.1021/jm0502541.
 45. Björkhem I, Leitersdorf E. Sterol 27-hydroxylase Deficiency: A Rare Cause of Xanthomas in Normcholesterolemic Humans. *Trends in Endocrinology & Metabolism*. 2000;11(5):180–3. doi:10.1016/s1043-2760(00)00255-1.
 46. Lorbek G, Lewinska M, Rozman D. Cytochromes P450 in Synthesis of Cholesterol and Bile Acids: From Mouse Models to Human Diseases. *FEBS Journal*. 2011. doi:10.1111/j.1742-4658.2011.08432.x.
 47. Fuller N, Hubbs J, Austin W, Creaser S, McKee T, Loureiro R, et al. The initial optimization of a new series of gamma-secretase modulators derived from a triterpene glycoside. *ACS Med Chem Lett*. 2012;3:908–13.
 48. Burg VK, Grimm HS, Rothhaar TL, Grösgen S, Hundsdoerfer B, Hauptenthal VJ, et al. Plant Sterols The Better Cholesterol in Alzheimer's Disease? A Mechanistical Study. *The Journal of Neuroscience*. 2013;33(41):16072–87. doi:10.1523/jneurosci.1506-13.2013.
 49. Urano Y, Ochiai S, Noguchi N. Suppression of amyloid- β production by 24S-hydroxycholesterol via inhibition of intracellular amyloid precursor protein trafficking. *The FASEB Journal*. 2013;27(10):4305–15. doi:10.1096/fj.13-231456.
 50. Irwin RW, Brinton RD. Allopregnanolone as regenerative therapeutic for Alzheimer's disease: Translational development and clinical promise. *Progress in Neurobiology*. 2014;113(0):40–55. doi:http://dx.doi.org/10.1016/j.pneurobio.2013.08.004.
 51. Amtul Z, Wang L, Westaway D, Rozmahel RF. Neuroprotective mechanism conferred by 17 β -estradiol on the biochemical basis of Alzheimer's disease. *Neuroscience*. 2010;169(2):781–6. doi:10.1016/j.neuroscience.2010.05.031.
 52. Sun J-H, Yu J-T, Tan L. The Role of Cholesterol Metabolism in Alzheimer's Disease. *Mol Neurobiol*. 2014;1–19. doi:10.1007/s12035-014-8749-y.
 53. Popp J, Lewczuk P, Kölsch H, Meichsner S, Maier W, Kornhuber J, et al. Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. *Journal of Neurochemistry*. 2012;123(2):310–6. doi:10.1111/j.1471-4159.2012.07893.x.
 54. Hubbs J, Fuller N, Austin W, Shen R, Creaser S, McKee T, et al. Optimization of a natural product-based class of gamma-secretase modulators. *J Med Chem*. 2012;55:9270–82.
 55. Holmes O, Paturi S, Ye W, Wolfe MS, Selkoe DJ. Effects of Membrane Lipids on the Activity and Processivity of Purified γ -Secretase. *Biochemistry*. 2012;51(17):3565–75. doi:10.1021/bi300303g.
 56. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, et al. Substrate-targeting γ -secretase modulators. *Nature*. 2008;453(7197):925–9. doi:http://www.nature.com/nature/journal/v453/n7197/supinfo/nature07055_S1.html.
 57. Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, et al. Lysine 624 of the Amyloid Precursor Protein (APP) Is a Critical Determinant of Amyloid β Peptide Length. *J Biol Chem*. 2011;286(46):39804–12. doi:10.1074/jbc.M111.274696.
 58. Jung JI, Ran Y, Cruz PE, Rosario AM, Ladd TB, Kukar TL, et al. Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ -Secretase Processivity Induced by γ -Secretase Modulators. *Biochemistry*. 2014;53(12):1947–57. doi:10.1021/bi401521t.
 59. Jung JI, Premraj S, Cruz PE, Ladd TB, Koo EH, et al. Independent Relationship between Amyloid Precursor Protein (APP) Dimerization and γ -Secretase Processivity. *PLoS ONE*. 2014;9(10):e111553. doi:10.1371/journal.pone.0111553.
 60. Sagi SA, Lessard CB, Winden KD, Maruyama H, Koo JC, Weggen S, et al. Substrate Sequence Influences γ -Secretase Modulator Activity, Role of the Transmembrane Domain of the Amyloid Precursor Protein. *J Biol Chem*. 2011;286(46):39794–803. doi:10.1074/jbc.M111.277228.
 61. Ohki Y, Higo T, Uemura K, Shimada N, Osawa S, Berezovska O, et al. Phenylpiperidine-type γ -secretase modulators target the transmembrane domain 1 of presenilin 1. *EMBO J*. 2011;30(23):4815–24. http://emboj.embopress.org/content/30/23/4815.long.
 62. Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, Bulic B, et al. Presenilin is the molecular target of acidic gamma-secretase modulators in living cells. *PLoS ONE*. 2012;7:e30484.
 63. Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, et al. Novel γ -Secretase Enzyme Modulators Directly Target Presenilin Protein. *J Biol Chem*. 2011;286(43):37181–6. doi:10.1074/jbc.C111.276972.
 64. Nelson ER, DuSelle CD, Wang X, Howe MK, Evans G, Michalek RD, et al. The Oxysterol, 27-Hydroxycholesterol, Links Cholesterol Metabolism to Bone Homeostasis Through Its Actions on the Estrogen and Liver X Receptors. *Endocrinology*. 2011;152(12):4691–705. doi:10.1210/en.2011-1298.
 65. Nelson ER, Chang C-y, McDonnell DP. Cholesterol and breast cancer pathophysiology. *Trends in Endocrinology & Metabolism*. 2014;25(12):649–55. doi:http://dx.doi.org/10.1016/j.tem.2014.10.001.
 66. Murphy MP, Uljon SN, Fraser PE, Fauq A, Lookingbill HA, Findlay KA, et al. Presenilin 1 regulates pharmacologically distinct γ -secretase activities. Implications for the role of presenilin in γ -secretase cleavage. *J Biol Chem*. 2000;275:26277–84.
 67. McLendon C, Xin T, Ziani-Cherif C, Murphy MP, Findlay KA, Lewis PA, et al. Cell-free assays for γ -secretase activity. *The FASEB Journal*. 2000. doi:10.1096/fj.00-0286fje.
 68. Kimberly WT, Esler WP, Ye W, Ostaszewski BL, Gao J, Diehl T, et al. Notch and the Amyloid Precursor Protein Are Cleaved by Similar γ -Secretase(s). *Biochemistry*. 2003;42(1):137–44. doi:10.1021/bi026888g.
 69. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, et al. Activity-dependent isolation of the presenilin- γ -secretase complex reveals nicastrin and a γ substrate. *Proc Natl Acad Sci USA*. 2002;99(5):2720–5. doi:10.1073/pnas.052436599.
 70. Fraering PC, Ye W, LaVoie MJ, Ostaszewski BL, Selkoe DJ, Wolfe MS. γ -Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site. *J Biol Chem*. 2005;280(51):41987–96. doi:10.1074/jbc.M501368200.
 71. Price AR, Xu G, Sieminski ZB, Smithson LA, Borchelt DR, Golde TE, et al. Comment on "ApoE-Directed Therapeutics Rapidly Clear β -Amyloid and Reverse Deficits in AD Mouse Models". *Science*. 2013;340(6135):924. doi:10.1126/science.1234089.
 72. Shen Q. Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. *Int J Nanomedicine*. 2011;6:1237–43.

73. Karu K, Hornshaw M, Woffendin G, Bodin K, Hamberg M, Alvelius G, et al. Liquid chromatography-mass spectrometry utilizing multi-stage fragmentation for the identification of oxysterols. *Journal of Lipid Research*. 2007;48(4):976–87. doi:10.1194/jlr.M600497-JLR200.
74. Jung JJ, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, et al. Steroids as γ -secretase modulators. *The FASEB Journal*. 2013;27(9):3775–85. doi:10.1096/fj.12-225649.
75. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Ab42 production. *Nat Med*. 2005;11(5):545–50. <http://www.nature.com/nm/journal/v11/n5/full/nm1235.html>.
76. Murphy MP, Uljon SN, Fraser PE, Fauq A, Lookingbill HA, Findlay KA, et al. Presenilin 1 regulates pharmacologically distinct γ -secretase activities: implications for the role of presenilin in γ -secretase cleavage. *J Biol Chem*. 2000;275(34):26277–84. doi:10.1074/jbc.M002812200.
77. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, et al. Anti-A β 42- and anti-A β 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. *J Clin Invest*. 2006;116(1):193–201. doi:10.1172/jci25410.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

